It is now accepted by many that early effective treatment is the best way to limit disability in the future and if you take that message on board that would destine the older platform therapies to the bin. They have lower side effect issues and work for some people but not well enough for the vast majority of people. Is it worth being in the 70% who fail, given the risk that what is lost is lost. This has been shown in trials what more evidence do the neuros need. Although interferon use has dropped there are still some places where this is a go-to treatment. Maybe they need to read this post as it is claimed there is some potenital to work out who will respond better….

Can artifical intellience overcome the lack of intelligence to not properly get the first sentence above and work out how interfeon betas can be used.

Ponce de León-Sánchez ER, Mendiola-Santibañez JD, Domínguez-Ramírez OA, Herrera-Navarro AM, Vázquez-Cervantes A, Jiménez-Hernández H, Acuña-García JA, Duarte-Pérez R, Álvarez-Alvarado JM. Artificial Intelligence Algorithm Based on Genetics to Predict Responses to Interferon-Beta Treatment in Multiple Sclerosis Patients. Bioengineering (Basel). 2026 Apr 30;13(5):523.

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that impacts nearly 3 million people worldwide. While the etiology and pathogenesis of MS are not yet fully understood, current evidence suggests that it results from complex interactions between genetic and environmental conditions. Clarifying the autoimmune mechanisms underlying MS remains a central objective in the development of effective therapeutic strategies. Interferon-beta (IFN-β) is one of the most frequently prescribed disease-modifying treatments for individuals with MS. However, despite its established efficacy, recent studies report that approximately 30-50% of patients exhibit inadequate response to IFN-β, largely due to genetic variability. Machine learning (ML), a branch of artificial intelligence (AI), employs data-driven computational models to enhance predictive accuracy and classification. In recent MS research, unsupervised learning techniques …..have been applied for classification purposes. However, these methods often fail to yield optimal solutions because they require numerous arbitrary decisions and perform adequately only when datasets contain clusters of similar sizes and lack significant outliers. Fuzzy systems (FSs) are designed to model complex, ambiguous real-world phenomena. In this study, an AI algorithm incorporating a fuzzy system, informed by expert neurologist input, is proposed to enhance the assignment of unknown class labels related to IFN-β response in MS patients. Additionally, a genetic algorithm is introduced to identify optimal solutions within the search space, facilitating hyperparameter optimization of a deep learning (DL) model trained with genetic biomarkers to identify patients likely to benefit from this therapy. Experimental results demonstrate that the fuzzy system achieved 80% classification efficiency, in contrast to 64% with conventional hierarchical clustering. Furthermore, an artificial neural network model, with hyperparameters optimized by the GA, achieved an accuracy of 0.8-1.0, surpassing the multi-layer perceptron, which achieved 0.6-0.8 accuracy using conventional tuning methods.

COI: None

Disclaimer: my views

Source: multiple-sclerosis-research.org